BofA analyst Kevin Fischbeck raised the firm’s price target on UnitedHealth (UNH) to $420 from $380 and keeps a Neutral rating on the shares. The tone of a discussion with the leadership team at the BofA Healthcare Conference was “bullish,” as the company is confident that it should be able to get back to at least the low end of its target margins in most businesses by 2028, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- Kevin Fischbeck Reaffirms Hold on Balanced Risk-Reward, Lifts Price Target to $420 on Improving Fundamentals and Margin Recovery Plans
- Moderately bullish activity in UnitedHealth with shares up 3.13%
- UnitedHealth’s Optum Rx Discloses New Pricing Model to Improve Transparency
- UnitedHealth’s Optum Rx announces ‘transparent’ pharmacy care model
- UnitedHealth to Present Strategy at Upcoming Healthcare Conference